These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. Intercell - accelerating innovation. Brehme M N Biotechnol; 2009 Apr; 25(4):181-4. PubMed ID: 19429533 [TBL] [Abstract][Full Text] [Related]
84. Overcoming the obstacles in the pharma/biotech industry: 2008 update. Graul AI; Revel L; Rosa E; Cruces E Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298 [TBL] [Abstract][Full Text] [Related]
85. Perspectives: biotechnology in Czech Republic, the past and the future. Damborský J; Prokop Z; Kostka M Biotechnol J; 2006 May; 1(5):487-90. PubMed ID: 16892283 [No Abstract] [Full Text] [Related]
86. The development of China's medical biotech industry needs to be driven by innovation. Yu Z; Dai Y Biotechnol J; 2006 Nov; 1(11):1253-7. PubMed ID: 17068752 [TBL] [Abstract][Full Text] [Related]
87. Peptides: isolation, production, and use in India. Nagaraj R Biotechnol J; 2009 Mar; 4(3):329-34. PubMed ID: 19156729 [No Abstract] [Full Text] [Related]
88. Overcoming the challenges in the pharma/biotech industry. Graul AI; Prous JR Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900 [TBL] [Abstract][Full Text] [Related]
89. HTS technologies in biopharmaceutical discovery. Wu G; Doberstein SK Drug Discov Today; 2006 Aug; 11(15-16):718-24. PubMed ID: 16846799 [TBL] [Abstract][Full Text] [Related]
90. Innovator Organizations in New Drug Development: Assessing the Sustainability of the Biopharmaceutical Industry. Kinch MS; Moore R Cell Chem Biol; 2016 Jun; 23(6):644-53. PubMed ID: 27341432 [TBL] [Abstract][Full Text] [Related]
91. Bioseparation in antibody manufacturing: the good, the bad and the ugly. Gottschalk U Biotechnol Prog; 2008; 24(3):496-503. PubMed ID: 18442255 [TBL] [Abstract][Full Text] [Related]
92. Plants for human health: greening biotechnology and synthetic biology. Moses T; Goossens A J Exp Bot; 2017 Jul; 68(15):4009-4011. PubMed ID: 28922776 [No Abstract] [Full Text] [Related]
93. Integrated continuous biomanufacturing: A new paradigm for biopharmaceutical production. Goudar CT; Titchener-Hooker N; Konstantinov K J Biotechnol; 2015 Nov; 213():1-2. PubMed ID: 26297904 [No Abstract] [Full Text] [Related]
94. Microtools for single-cell analysis in biopharmaceutical development and manufacturing. Love KR; Bagh S; Choi J; Love JC Trends Biotechnol; 2013 May; 31(5):280-6. PubMed ID: 23582471 [TBL] [Abstract][Full Text] [Related]
95. Recent advances in whole cell biocatalysis techniques bridging from investigative to industrial scale. Wachtmeister J; Rother D Curr Opin Biotechnol; 2016 Dec; 42():169-177. PubMed ID: 27318259 [TBL] [Abstract][Full Text] [Related]
96. Industry perspectives on the development of biologics. Kramer BC PM R; 2011 Jun; 3(6 Suppl 1):S132-5. PubMed ID: 21703570 [No Abstract] [Full Text] [Related]
97. Industrially feasible alternative approaches in the manufacture of solid dispersions: a technical report. Karanth H; Shenoy VS; Murthy RR AAPS PharmSciTech; 2006 Oct; 7(4):87. PubMed ID: 17233539 [TBL] [Abstract][Full Text] [Related]
98. JPMorgan 25th annual healthcare conference. Pipelines from NovaCardia, Quark Biotech, Raven Biotechnologies and Serenex. Robins P IDrugs; 2007 Mar; 10(3):152-5. PubMed ID: 17351863 [No Abstract] [Full Text] [Related]
99. Case study and application of process analytical technology (PAT) towards bioprocessing: use of on-line high-performance liquid chromatography (HPLC) for making real-time pooling decisions for process chromatography. Rathore AS; Yu M; Yeboah S; Sharma A Biotechnol Bioeng; 2008 Jun; 100(2):306-16. PubMed ID: 18078292 [TBL] [Abstract][Full Text] [Related]